Al­con takes a new look at oph­thalmic phar­ma space and mar­ket­ing, post No­var­tis spin­out and raft of ac­qui­si­tions

When Al­con eye care spun out of No­var­tis as an in­de­pen­dent com­pa­ny, the oph­thal­mol­o­gy phar­ma­ceu­ti­cals busi­ness stayed at the Big Phar­ma. For Al­con, though, it was an “ob­vi­ous” gap in its eye care and eye health ex­per­tise, so it went out and be­gan ac­quir­ing and build­ing out a pre­scrip­tion eye drug port­fo­lio.

Now four years af­ter a hand­ful of ac­qui­si­tions — in­clud­ing a $770 mil­lion deal last Au­gust for Aerie Phar­ma­ceu­ti­cals with two eye pre­scrip­tion meds plus a late-stage dry eye dis­ease can­di­date — Al­con is step­ping out with new mar­ket­ing around its grow­ing phar­ma port­fo­lio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.